Post Stroke Dysphagia: Effect of Adding rTMS to Conventional Therapy on the Prevalence of Pneumonia.
Launched by CAIRO UNIVERSITY · Nov 7, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating whether adding a treatment called repetitive transcranial magnetic stimulation (rTMS) to standard swallowing therapy can reduce the risk of pneumonia in patients who have difficulty swallowing after a stroke. Difficulty swallowing, known as dysphagia, is a serious problem for stroke survivors, as it can lead to aspiration pneumonia, which is when food or liquid goes into the lungs and causes infection. Researchers aim to see if rTMS, which helps improve swallowing function, can also lower the chances of developing pneumonia in these patients.
To participate in the study, individuals must be between 49 and 65 years old and have been diagnosed with moderate to severe swallowing difficulties due to a recent stroke. They should be able to follow instructions and sit up properly during treatment. However, those with prior strokes, previous swallowing issues, certain head and neck surgeries, lung diseases, or serious cognitive problems will not be eligible. Participants can expect to engage in both the standard swallowing therapy and the rTMS treatment during the trial. This study is important because it could lead to better care and outcomes for stroke survivors facing swallowing challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. All the patients were diagnosed of stroke oropharyngeal dysphagia by a neurologist. Sever to moderate dysphagia (GUSS 0-14).
- • 2. Severity of stroke ranged from mild to moderate according to NIHSS score (NIHSS less than or equal 16).
- • 3. Patients' age ranged from 49 to 65 years old.
- • 4. Patients had the ability to understand and follow instructions.
- • 5. Patients were able to sit in upright position.
- Exclusion Criteria:
- • 1. History of previous stroke.
- • 2. History of any swallowing problem.
- • 3. History of any head and neck surgery or tumor that causes swallowing dysfunction.
- • 4. Any lung disease or pneumonia on admission.
- • 5. Patients with cognitive deficits or disturbed conscious level.
- • 6. Patients on mechanical ventilator.
- • 7. Patients with sensory or global aphasia.
About Cairo University
Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Giza, , Egypt
Giza, Ad Doqi, Giza District, Giza Governorate, Egypt
Patients applied
Trial Officials
Engy B. Moustafa, PhD
Principal Investigator
Faculty of Physical Therapy, Cairo University, Egypt
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported